FAS and neoplasm: Drug delivery systems deliver metabolism-regulating drugs (e.g., glycolysis inhibitors, FAS inhibitors, etc.)to tumor cells through biomaterial carriers such as nanoparticles, liposomes, polymers, etc. to inhibit their metabolic aberrations, reducing the growth and spread of the tumor cells, which is the most dominant approach at present [498].